| 研究報告 2026 年 01 月 23 日 上海寶濟藥業 | 02659.HK 步入商業化初期的生物技術公司 評級 買入 目標價 HK$ 111.30 上海寶濟藥業(02659.HK)為一家生物技術公司，利用合成生物技術開發及提供重組 生物藥物，專注於攻克治療選擇有限且製造工藝複雜的病症。集團現時專注於開發 四個戰略治療領域的候選藥物，包括 i) 大容量皮下給藥，ii) 抗體介導的自身免疫 性疾病，iii) 輔助生殖藥物，及 iv) 其他重組生物製品。集團已建立一條由一款已獲 批藥物、七款處於臨床階段的候選藥物及四項臨床前資產組成的產品管線。 產品於中國具有先發優勢: 產品已被認證有效並成功商業化: 重組人透明質酸酶及長效 FSH產品於國外部份地 區已經被使用及成功商業化，反映兩款藥物在市場上存在需求，同時能夠為藥企及 股東帶來經濟價值。根據國外的經驗，上海寶濟藥業(02659.HK)兩款核心產品 KJ017 及 SJ02 能夠成功商業化並取得利潤的確定性較創新藥物為高，特別是集團具有先 發優勢，且能夠基於國外企業的經驗上建立獨特的商業合作模式。 明確的商業化模式與時間表: 就即將及正在商業化的產品而言， ...

三季度经营平稳，机器人和液冷迎新增长 德昌电机控股(0179) | [姓名table_Authors] | 电话 | 邮箱 | 登记编号 | | --- | --- | --- | --- | | 刘一鸣(分析师) | 021-23154145 | liuyiming@gtht.com | S0880525040050 | | 石佳艺(分析师) | 021-38676666 | shijiayi@gtht.com | S0880525070001 | | 张予名(研究助理) | 021-23154145 | zhangyuming@gtht.com | S0880125042241 | 投资要点： 股 票 研 究 本报告导读： 德昌电机 2025-2026 财年前三季度经营平稳，后续机器人和液冷产业发展将为公司 带来全新发展动力，维持"增持"评级。 股票研究 /[Table_Date] 2026.01.23 [Table_Industry] 运输设备业 | | | [当前价格 Table_CurPrice] (港元)： 30.66 | 财务摘要(百万美元) | 2025A | 2026E | 2027E | ...

Investment Rating - The report does not specify a clear investment rating for the company [6] Core Insights - The company has demonstrated strong operational capabilities in IP management, with recent product innovations leading to increased sales potential for Q1 [1][2] - Recent stock buybacks, totaling over 300 million HKD, reflect the company's confidence in its long-term growth prospects and indicate that the stock price is at a relatively low level [1][3] - The company has successfully launched new product lines that have gained significant market traction, suggesting a robust ability to diversify its IP portfolio [2] Summary by Sections Product Performance - The Pucky Knock Knock series blind boxes have gained popularity, showcasing the company's innovative approach to IP [2] - The company has also launched successful series for the New Year and Valentine's Day, indicating strong consumer demand [2] Stock Buyback Activity - The company repurchased 1.4 million shares at an average price of 161 HKD and 500,000 shares at 173 HKD, demonstrating confidence in its stock valuation [3] - The stock buybacks are seen as a strategic move to bolster market confidence and counteract short-selling pressures [3] Market Outlook - The company has a strong presence in overseas markets, with approximately 200 stores globally, and continues to expand its footprint [4] - Future revenue projections indicate significant growth, with expected revenues of 373.98 billion RMB in 2025, reflecting a year-over-year growth of 186.8% [12] - The company's P/E ratios for 2025, 2026, and 2027 are projected to be 20.70, 15.25, and 12.26 respectively, suggesting that the current valuation is relatively low for a high-growth company [4][12]

Investment Rating - The report assigns a "Buy" rating for the company, indicating a positive outlook for its stock performance [5]. Core Insights - The company is leading the ADC (Antibody-Drug Conjugate) iteration wave and is expected to achieve commercialization by 2026 [2][3]. - The company has received IND approval for its self-developed ADAM9 ADC drug DB-1317, allowing clinical trials in late-stage metastatic solid tumor patients [2]. - The HER2 ADC DB-1303 has reached its primary endpoint in a Phase III clinical trial for HER2-positive unresectable or metastatic breast cancer, accelerating its path to market [3]. - The company is expected to report significant clinical data in 2026, which could enhance its market position and revenue potential [9]. Financial Forecasts - Projected revenues for the company are as follows: 1,941 million RMB in 2024, 1,950 million RMB in 2025, 1,972 million RMB in 2026, and 2,100 million RMB in 2027, with growth rates of 8.7%, 0.5%, 1.1%, and 6.5% respectively [4]. - The net profit attributable to shareholders is forecasted to be -1,050 million RMB in 2024, -247 million RMB in 2025, -386 million RMB in 2026, and -341 million RMB in 2027, showing a significant improvement in 2025 with a growth rate of 76.5% [4]. - Earnings per share (EPS) are expected to be -11.75 RMB in 2024, -2.76 RMB in 2025, -4.31 RMB in 2026, and -3.82 RMB in 2027 [4].

SDICSI 2026 年 1 月 23 日 泡泡玛特(9992.HK) IP 持续出圈印证运营能力，回购体现公司信心 事件：近期，公司在品类上做了更多的创新尝试，PUCKY 敲敲系列盲盒的出 圈、星星人怦然星动系列销售火热、以及新年马力全开系列毛绒受热捧，都印 证了公司对 IP 的运营能力，预计给 Q1 的销售带来更多增量。此外，公司近 日连续进行回购，1 月 19 日和 1 月 21 日共斥资超 3 亿港元进行回购，这也 彰显了公司对于中长期发展的信心。此前股价已从顶部下跌近 4 成，近期估值 开始修复，但仍处于合理偏低水平，推荐持续关注。 报告摘要 新品持续热销，有望给 Q1 的销售带来更多增量。近期，泡泡玛特 Pucky 敲敲 系列盲盒出圈，该产品是泡泡玛特旗下 IP 之一 Pucky 毕奇的最新系列"Pucky 敲敲系列搪胶毛绒挂件"，售价 99 元/盒，有"机敏"、"快乐"、"缘分"、"幸 运"、"智慧"、"财富"和隐藏款"成功"。产品特性是带有声音互动功能，通过 拍打毕奇脑袋，可以发出清脆的类似敲击木鱼的声音，符合当下打工人热爱玄 学的精神状态。该系列也因其敲击玩法被称为"电子木鱼"而出圈，和此 ...

曲公司 非領令融 2026 年 01 月 23 日 中国船舶積領 通过可转债实现低利率融资,特别分红重视股东回报 报告原因：有信息公布需要点评 (维持) | 市场数据: | 2026 年 01 月 22 日 | | --- | --- | | 收盘价（港币） | 2.14 | | 恒生中国企业指数 | 9114.3 | | 52 周最高/最低（港币) | 2.40/1.55 | | H 股市值（亿港币） | 132.66 | | 流通 H 股（百万股） | 6,199.22 | | 汇率（港币/人民币） | 0.8982 | 一年内股价与基准指数对比走势: 51% 31% 资料来源：Bloomberg 相关研究 证券分析师 王晨鉴 A0230525030001 wangcj@swsresearch.com 闫海 A0230519010004 yanhai@swsresearch.com 联系人 王晨鉴 A0230525030001 wangcj@swsresearch.com 申万宏源研究微信服务号 投资要点: 财务数据及盈利预测 | 港元 | 2023 | 2024 | 2025E | 2026E | 20 ...

Investment Rating - The report assigns a "Buy" rating for the company, indicating a positive outlook for its stock performance [5]. Core Insights - The company is leading the ADC (Antibody-Drug Conjugate) innovation wave and is expected to achieve commercialization by 2026 [2][3]. - The company has received IND approval for its self-developed ADAM9 ADC drug DB-1317, allowing clinical trials in late-stage metastatic solid tumor patients [2]. - The HER2 ADC DB-1303 has reached its primary endpoint in a Phase III clinical trial for HER2-positive unresectable or metastatic breast cancer, accelerating its market approval process [3]. - The company is expected to report multiple clinical data readouts in 2026, which could significantly impact its growth trajectory [9]. Financial Forecasts - Projected revenues for 2024, 2025, 2026, and 2027 are 1,941 million, 1,950 million, 1,972 million, and 2,100 million RMB respectively, with growth rates of 8.7%, 0.5%, 1.1%, and 6.5% [4]. - The net profit attributable to shareholders is forecasted to be -1,050 million, -247 million, -386 million, and -341 million RMB for the same years, reflecting growth rates of -193.8%, 76.5%, -56.1%, and 11.5% [4]. - Earnings per share (EPS) are expected to be -11.75, -2.76, -4.31, and -3.82 RMB for 2024, 2025, 2026, and 2027 respectively [4]. Clinical Development and Pipeline - The company is advancing its ADC pipeline, including DB-1316, which aims to address existing ADC resistance issues and is set to enter clinical stages soon [9]. - Collaborations with BioNtech are expected to yield significant clinical data in 2026, enhancing the company's competitive position in the ADC market [9].

上 市 公 司 非银金融 2026 年 01 月 23 日 中国船舶租赁 (03877) ——通过可转债实现低利率融资，特别分红重视股东回报 报告原因：有信息公布需要点评 买入（维持） | 市场数据： | 2026 年 01 月 22 日 | | --- | --- | | 收盘价（港币） | 2.14 | | 恒生中国企业指数 | 9114.3 | | 52 周最高/最低（港币） | 2.40/1.55 | | H 股市值（亿港币） | 132.66 | | 流通 H 股（百万股） | 6,199.22 | | 汇率（港币/人民币） | 0.8982 | 一年内股价与基准指数对比走势： -9% 11% 31% 51% HSCEI 中国船舶租赁 资料来源：Bloomberg 相关研究 - 证券分析师 投资要点： 财务数据及盈利预测 | 港元 | 2023 | 2024 | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业总收入（百万元） | 3,745 | 4,441 | 4,286 | 4,541 | 4,821 | | 同 ...

Investment Rating - The report assigns a "Buy" rating to the company with a target price of HKD 15.00, representing a potential upside of 37.7% from the current price of HKD 10.89 [6]. Core Insights - The company is expected to achieve a net profit of HKD 2.53 billion to HKD 2.57 billion in 2025, reflecting a growth of 45% to 60% compared to 2024, which aligns with the company's equity incentive targets [8]. - The TV segment has shown significant improvement, with a 5.3% increase in TV shipments to 21.08 million units in the first three quarters of 2025, and a remarkable 153% growth in global shipments of TCL MiniLED TVs [8]. - A joint venture with Sony is set to enhance global and high-end development, with TCL holding a 51% stake. This partnership is expected to leverage TCL's supply chain and cost control advantages alongside Sony's advanced imaging technology and brand value [8]. - The report anticipates that the collaboration will allow TCL to transition from "scale expansion" to "brand globalization," enhancing its market share in high-end segments [8]. Financial Summary - Revenue is projected to grow from HKD 78.99 billion in 2023 to HKD 153.96 billion by 2027, with a compound annual growth rate (CAGR) of 13.5% [4]. - The gross profit margin is expected to stabilize around 15.7% by 2027, with net profit increasing from HKD 744 million in 2023 to HKD 3.51 billion in 2027 [4][9]. - Earnings per share (EPS) is forecasted to rise from HKD 0.33 in 2023 to HKD 1.39 in 2027, indicating a strong growth trajectory [4][9]. - The company’s price-to-earnings (P/E) ratio is projected to decrease from 32.9x in 2023 to 7.8x by 2027, suggesting an attractive valuation as earnings grow [4].

港股通 回购彰显成长信心，产品持续出奇创新 证券研究报告 泡泡玛特 (9992 HK) | 华泰研究 | | | 动态点评 | 投资评级(维持): | 买入 | | --- | --- | --- | --- | --- | --- | | 2026 年 | 1 月 | 22 日│中国香港 | 消费轻工 | 目标价(港币): | 410.00 | 公司近日开启股份回购，1 月 19 日、21 日两次回购合计 190 万股，回购金 额 3.1 亿港元。公司曾于 4M23-2M24 持续回购，累计约 2465 万股，金额 约 4.6 亿港元，平均单笔 36 万股。本轮回购的单笔金额及股数均超过以往， 彰显公司对成长前景信心。公司在门店运营精细度、场景氛围、情感体验等 方面不断精进，已长期论证的 IP 创新、品类创新能力持续发力，不断带动 新 IP、新玩法出圈。我们看好公司在 26 年加快 IP 结构多元化、均衡化， 乐园、动画内容、甜品、饰品等业态加快落地，培育新增长点并强化 IP 情 感连接，缓解市场对时尚风险的担忧。维持"买入"评级，继续重点推荐。 新品玩法、创意不断出新，持续验证 IP 运营能力 近期公司多 ...